Search Results - "Campos Balea, Begona"

Follow-up of primary melanoma patients with high risk of recurrence: recommendations based on evidence and consensus by Campos-Balea, Begoña, Fernández-Calvo, Ovidio, García-Figueiras, Roberto, Neira, Carlos, Peña-Penabad, Carmen, Rodríguez-López, Carmela, Vílchez-Simo, Rocío, Quindós-Varela, María

“…In spite of the good prognosis of patients with early-stage melanoma, there is a substantial proportion of them that develop local or distant relapses. With…”
Get full text

Durable Response to Vemurafenib and Cobimetinib for the Treatment of BRAF-Mutated Metastatic Melanoma in Routine Clinical Practice by Álamo, Mª Del Carmen, Ochenduszko, Sebastian, Crespo, Guillermo, Corral, Mónica, Oramas, Juana, Sancho, Pilar, Medina, Javier, Garicano, Fernando, López, Pedro, Campos Balea, Begoña, Rodríguez Garzotto, Analia, Muñoz-Couselo, Eva

“…The combination of and inhibitors delays the onset of resistance and provides more sustained and dramatic responses in comparison with a inhibitor in…”
Get full text

Prognostic factors for survival in patients with metastatic lung adenocarcinoma: An analysis of the SEER database by Campos‐Balea, Begoña, Castro Carpeño, Javier, Massutí, Bartomeu, Vicente‐Baz, David, Pérez Parente, Diego, Ruiz‐Gracia, Pedro, Crama, Leonardo, Cobo Dols, Manuel

“…Background Lung adenocarcinoma (ADC) is the main cause of death related to lung cancer. The aim of this study was to identify poor prognostic factors for…”
Get full text

Real world data of nivolumab for previously treated non-small cell lung cancer patients: a Galician lung cancer group clinical experience by Areses Manrique, Mª Carmen, Mosquera Martínez, Joaquín, García González, Jorge, Afonso Afonso, Francisco Javier, Lázaro Quintela, Martín, Fernández Núñez, Natalia, Azpitarte Raposeiras, Cristina, Amenedo Gancedo, Margarita, Santomé Couto, Lucía, García Campelo, Mª Rosario, Muñoz Iglesias, Jose, Cortegoso Mosquera, Alexandra, Vilchez Simo, Rocío, Casal Rubio, Joaquín, Campos Balea, Begoña, Carou Frieiro, Iria, Alonso-Jaudenes Curbera, Guillermo, Anido Herranz, Urbano, García Mata, Jesus, Fírvida Pérez, José Luis

Get full text

Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor–Targeted Agents by Angelergues, Antoine, Efstathiou, Eleni, Gyftaki, Revekka, Wysocki, Piotr Jan, Lainez, Nuria, Gonzalez, Iria, Castellano, Daniel E., Ozguroglu, Mustafa, Carbonero, Iciar Garcia, Flechon, Aude, Borrega, Pablo, Guillot, Aline, Balea, Begona Campos, Le Moulec, Sylvestre, Esteban, Emilio, Munarriz, Javier, Rubio, Gustavo, Birtle, Alison J., Delanoy, Nicolas, Bellmunt, Joaquim, Oudard, Stéphane

“…Several agents have demonstrated an overall survival (OS) benefit in metastatic castration-resistant prostate cancer (mCRPC); however, optimal sequencing is…”
Get full text

PD-L1 Inhibitors as Monotherapy for the First-Line Treatment of Non-Small-Cell Lung Cancer in PD-L1 Positive Patients: A Safety Data Network Meta-Analysis by García Campelo, María Rosario, Arriola, Edurne, Campos Balea, Begoña, López-Brea, Marta, Fuentes-Pradera, José, de Castro Carpeno, Javier, Aguado, Carlos, Pérez Parente, Diego, de Oro Pulido, Fidel, Ruiz-Gracia, Pedro, Rodríguez-Abreu, Delvys

“…This network meta-analysis (NMA) evaluates the safety of first-line programmed death-ligand 1 (PD-L1) inhibitor monotherapy in advanced NSCLC patients compared…”
Get full text

PD-(L)1 Inhibitors in Combination with Chemotherapy as First-Line Treatment for Non-Small-Cell Lung Cancer: A Pairwise Meta-Analysis by García-González, Jorge, Ruiz-Bañobre, Juan, Afonso-Afonso, Francisco J, Amenedo-Gancedo, Margarita, Areses-Manrique, María Del Carmen, Campos-Balea, Begoña, Casal-Rubio, Joaquín, Fernández-Núñez, Natalia, Fírvida Pérez, José Luis, Lázaro-Quintela, Martín, Pérez Parente, Diego, Crama, Leonardo, Ruiz-Gracia, Pedro, Santomé-Couto, Lucía, León-Mateos, Luis

“…The combination of programmed cell death-1 (PD-1)/programmed death ligand-1 (PD-L1) inhibitors with chemotherapy has emerged as a promising therapeutic option…”
Get full text

Molecular basis of hypertension side effects induced by sunitinib by Aparicio-Gallego, Guadalupe, Afonso-Afonso, Francisco J, León-Mateos, Luis, Fírvida-Pérez, Jose L, Vázquez-Estévez, Sergio, Lázaro-Quintela, Martín, Ramos-Vázquez, Manuel, Fernández-Calvo, Ovidio, Campos-Balea, Begoña, Antón-Aparicio, Luis M

“…Over the past decade a number of vascular complications have emerged, such as newly developed or worsened hypertension, in patients who were administered with…”
Get full text

Identification of non-actionable mutations with prognostic and predictive value in patients with advanced or metastatic non-small cell lung cancer by Provencio-Pulla, Mariano, Pérez-Parente, Diego, Olson, Sara, Hasan, Haroon, Balea, Begoña Campos, Rodríguez-Abreu, Delvys, Piqueras, Marta López-Brea, Pal, Navdeep, Wilkinson, Samantha, Vilas, Esther, Ruiz-Gracia, Pedro, Cobo-Dols, Manuel

“…Introduction Lung cancer is one of the most prevalent cancers and the leading cause of cancer death. Advanced non-small cell lung cancer (aNSCLC) patients…”
Get full text

SEOM-GEM clinical guidelines for cutaneous melanoma (2023) by Márquez-Rodas, Iván, Muñoz Couselo, Eva, Rodríguez Moreno, Juan F., Arance Fernández, Ana Mª, Berciano Guerrero, Miguel Ángel, Campos Balea, Begoña, de la Cruz Merino, Luis, Espinosa Arranz, Enrique, García Castaño, Almudena, Berrocal Jaime, Alfonso

“…Cutaneous melanoma incidence is rising. Early diagnosis and treatment administration are key for increasing the chances of survival. For patients with…”
Get full text

Immune checkpoint inhibitor-associated thrombosis in patients with bladder and kidney cancer: a study of the Spanish Society of Medical Oncology (SEOM) thrombosis and cancer group by Sánchez Cánovas, Manuel, Fernández Garay, David, Adoamnei, Evdochia, Guirao García, Esperanza, López Robles, Javier, Cacho Lavin, Diego, Martínez de Castro, Eva, Campos Balea, Begoña, Garrido Fernández, Alberto, Fernández Pérez, Isaura, Ferrández Arias, Asia, Suarez, Noelia, Quintanar Verduguez, Teresa, Lobo de Mena, Miriam, Rodríguez, Laura, Gutierrez, David, Martín Fernández de Soiginie, Ana Manuela, García Adrián, Silvia, Ferrer Pérez, Ana Isabel, Delgado Heredia, María Jesús, Muñoz Lerma, Amelia, Luque, Raquel, Mazariegos Rubí, Manuel, Rúperez Blanco, Ana Belen, García Escobar, Ignacio, Mendiola, Jaime, Muñoz Martín, Andrés Jesús

“…Purpose Both venous and arterial thrombotic events (VTE/AT) can be associated with immune checkpoint inhibitors (ICI). However, there is a paucity of…”
Get full text

Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group by Arias Ron, David, Areses Manrique, Maria Carmen, Mosquera Martínez, Joaquín, García González, Jorge, Afonso Afonso, Francisco Javier, Lázaro Quintela, Martín, Fernández Núñez, Natalia, Azpitarte Raposeiras, Cristina, Amenedo Gancedo, Margarita, Santomé Couto, Lucía, García Campelo, María Rosario, Muñoz Iglesias, Jose, Ruiz Bañobre, Juan, Vilchez Simo, Rocío, Casal Rubio, Joaquín, Campos Balea, Begoña, Carou Frieiro, Iria, Alonso-Jaudenes Curbera, Guillermo, Anido Herranz, Urbano, García Mata, Jesús, Fírvida Pérez, Jose Luis

“…Nivolumab is an anti PD1 immunotherapy drug approved for advanced Non-Small Cell Lung Cancer (NSCLC) patients who previously received at least one prior line…”
Get full text

Observational cross-sectional study evaluating the sociodemographic and clinical characteristics of patients with metastatic melanoma harboring a BRAF V600 mutation, treated with cobimetinib and vemurafenib based on routine clinical practice by Álamo de la Gala, Maria Carmen, Ochenduszko, Sebastian, Crespo, Guillermo, Corral, Monica, Oramas Rodriguez, Juana Maria, Sancho, Maria Pilar, Medina, Javier, Garicano Goldaraz, Fernando, López Leiva, Pedro, Campos Balea, Begona, Rodriguez, Analia Adela, Muñoz-Couselo, Eva

“…Abstract only e22028 Background: The drug combination of BRAF inhibitors with MEK inhibitors delays the onset of resistance and enhances apoptosis. Objectives:…”
Get full text

Predictors for survival with cabazitaxel (CBZ) in metastatic, castration-resistant prostate cancer (mCRPC): Long term follow-up of the Spanish registry by González-Maeso, Iria, Lainez, Nuria, Castellano, Daniel, Garcia Carbonero, Iciar, Borrega, Pablo, Campos Balea, Begona, Garcia Marrero, Rosa, Esteban, Emilio, Rodriguez Vida, Alejo, Munarriz, Javier, Garcia-Bueno, Jose Maria, Villalobos, Maria L., Viciana, Ruth, Rubio, Gustavo, Perez-Valderrama, Begoña, Garcia Sanchez, Jose, Pelaez Lorenzo, Beatriz, Cumplido Buron, Jose David, Martin, Almudena, Bellmunt, Joaquim

“…Abstract only e602 Background: The clinical experience with CBZ in mCRPC patients (pts) has enriched notably since its approval for clinical use, but there is…”
Get full text

Sequencing in metastatic castration-resistant prostate cancer (mCRPC): Updated results of the FLAC International Database by Delanoy, Nicolas, Angelergues, Antoine, Efstathiou, Eleni, Gyftaki, Revekka, Wysocki, Piotr Jan, Lainez, Nuria, Gonzalez, Iria, Castellano, Daniel E., Ozguroglu, Mustafa, Garcia Carbonero, Iciar, Flechon, Aude, Borrega, Pablo, Guillot, Aline, Campos Balea, Begona, Le Moulec, Sylvestre, Esteban, Emilio, Munarriz, Javier, Barker, Claire, Birtle, Alison J., Oudard, Stephane

“…Abstract only 267 Background: Optimal sequencing of new androgen-receptor targeted agents (ART) abiraterone and enzalutamide with docetaxel (DOC) and…”
Get full text

Consistent benefit survival with cabazitaxel (CBZ) in metastatic castration resistant prostate cancer (mCRPC) in Spain: Updated results by Gonzalez, Iria, Castellano, Daniel E., Esteban, Emilio, Pérez Arnillas, Quionia, Munarriz, Javier, Campos Balea, Begona, Garcia-Bueno, Jose Maria, Villalobos Leon, M. Laura, Laínez, Nuria, Rubio, Gustavo, Santander, Carmen, Cumplido Buron, Jose David, Garcia Sanchez, Jose, Martin, Almudena, Pelaez Lorenzo, Beatriz, Reyes Garcia, Ana, Anido Herranz, Urbano, Perez-Valderrama, Begoña, Yglesias, Jose Maria, Bellmunt, Joaquim

“…Abstract only…”
Get full text

The FAM-GEM-1 study: Frequency and characteristics of familial melanoma in Spain by Marquez Rodas, Ivan, Martin-Gonzalez, Manuel, Nagore, Eduardo, Gomez Fernandez, Cristina, Aviles Izquierdo, Jose Antonio, Maldonado-Seral, Cayetana, Soriano, Virtudes, Majem, Margarita, Coloma, Virginia Palomar, Maseda, Rocio, Martin-Carnicero, Alfonso, Puértolas, Teresa, Godoy Gijon, Elena, Cerezuela, Pablo, Ochoa de Olza, Maria, Campos Balea, Begona, Perez Ruiz, Elisabeth, Soria Rivas, Ainara, Gil-Arnaiz, Irene, Martin-Algarra, Salvador

“…Abstract only…”
Get full text

Meaningful survival after cabazitaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): The Spanish experience by Gonzalez Maeso, Iria, Castellano, Daniel E., Campos Balea, Begona, Esteban, Emilio, Pérez Arnillas, Quionia, Villalobos Leon, M. Laura, Munarriz, Javier, Rubio, Gustavo, Cumplido Buron, Jose David, Garcia Sanchez, Jose, Martin, Almudena, Garcia-Bueno, Jose Maria, Reyes Garcia, Ana, Perez-Valderrama, Begoña, Anido Herranz, Urbano, Bellmunt, Joaquim

“…Abstract only 235 Background: New emerging therapies for metastatic castration resistant prostate cancer (mCRPC), such as cabazitaxel (CBZ), have prompted the…”
Get full text

GGCP041/09: A Galician study of second-line erlotinib in patients with advanced non-squamous non-small cell lung cancer (nsNSCLC) by Vazquez Estevez, Sergio, Villanueva Silva, Maria Jose, Firvida Perez, Jose Luis, Lazaro Quintela, Martin, Varela Ferreiro, Silvia, Huidobro Vence, Gerardo, Fernandez Calvo, Ovidio, Campos Balea, Begona, Casal Rubio, Joaquin, Areses Manrique, Carmen

“…Abstract only e18146 Background: Efficacy of oral erlotinib has been conclusively established in 2 nd line setting (BR.21 and TRUST studies) and the outcomes…”
Get full text

Erlotinib as frontline treatment for elderly patients (p) with advanced nonsquamous non-small cell lung cancer (nsNSCLC): GGCP044/09 study by Firvida Perez, Jose Luis, Vazquez Estevez, Sergio, Casal Rubio, Joaquin, Alonso Bermejo, Miguel, Varela Ferreiro, Silvia, Villanueva Silva, Maria Jose, Afonso Afonso, Francisco J., Lazaro Quintela, Martin, Areses Manrique, Carmen, Campos Balea, Begona, Huidobro Vence, Gerardo, Fernandez Calvo, Ovidio, Alvarez Gomez, Elena, Grande Ventura, Carlos, Fernandez Montes, Ana, Castro Gomez, Enrique, Mel Lorenzo, Jose Manuel

“…Abstract only e18040 Background: NSCLC is primarily a disease of older people with a median age of approximately 70 years (y) at diagnosis. Platinum…”
Get full text